2020
Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas
Deng S, Fan Z, Gong Y, Cheng H, Jin K, Qian Y, Xiao Z, Liu Y, Wang R, Zheng Y, Ni Q, Yu X, Liu C, Luo G. Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas. Experimental And Therapeutic Medicine 2020, 20: 158. PMID: 33093896, PMCID: PMC7571373, DOI: 10.3892/etm.2020.9287.Peer-Reviewed Original ResearchMucinous cystic neoplasmsSerum CA125Carcinoembryonic antigenMalignant changeReceiver operating characteristicCystic neoplasmsCarbohydrate antigenPredictive value of CA125Serum carbohydrate antigenSerum carcinoembryonic antigenPredictive of malignancyValue of CA125CA19-9Predicting malignancyMalignant potentialInvasive groupSerum levelsCA125Grade groupPredictive valueSerumPredictive roleHigh gradeClinical implicationsAntigen
2012
CD24-Siglec-G Interaction Plays an Important in Reducing Experimental Graft-Versus-Host Disease (GVHD)
Toubai T, Evers R, Sun Y, Tawara I, Liu C, Tamaki H, Mathewson N, Nieves E, Bassetti M, Zheng P, Liu Y, Reddy P. CD24-Siglec-G Interaction Plays an Important in Reducing Experimental Graft-Versus-Host Disease (GVHD). Blood 2012, 120: 453. DOI: 10.1182/blood.v120.21.453.453.Peer-Reviewed Original ResearchHost antigen presenting cellsAntigen presenting cellsBALB/c donorsT cellsWT B6Allogeneic BMTImmunoreceptor tyrosine-based inhibitory motifWorse survivalSerum levelsImmune activationBM chimerasDonor T cell expansionAllogeneic T-cell responsesT cell responsesBALB/c T cellsPro-inflammatory cytokinesT cell expansionRelevant murine modelRole of SiglecsC donorsIg-like lectinsIntensity of conditioningGraft-VersusGVHD mortalityHigher GVHDSerum levels of soluble CD25 as a marker for hepatocellular carcinoma
CABRERA R, FITIAN A, ARARAT M, XU Y, BRUSKO T, WASSERFALL C, ATKINSON M, LIU C, NELSON D. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncology Letters 2012, 4: 840-846. PMID: 23205111, PMCID: PMC3506698, DOI: 10.3892/ol.2012.826.Peer-Reviewed Original ResearchSerum levelsEarly hepatocellular carcinomaHepatocellular carcinomaHCC presenceSoluble CD25Pg/Levels of sCD25Healthy control subjectsNovel predictive markerAdvanced cirrhosisPresent study studyAdvanced fibrosisTumor burdenTumor stageControl subjectsHCC patientsPredictive markerImmune factorsGlobal unmet needLarge cohortSCD25PatientsSmall seriesUnmet needSignificant positive correlation
2004
Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease
Maeda Y, Levy R, Reddy P, Liu C, Clouthier S, Teshima T, Ferrara J. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood 2004, 105: 2023-2027. PMID: 15466930, DOI: 10.1182/blood-2004-08-3036.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnimalsBone Marrow TransplantationCD8-Positive T-LymphocytesCell Culture TechniquesFas Ligand ProteinGraft vs Host DiseaseHistocompatibilityHistocompatibility Antigens Class ILymphocyte TransfusionMembrane GlycoproteinsMiceMice, Inbred StrainsModels, AnimalPerforinPore Forming Cytotoxic ProteinsTransplantation, HomologousConceptsT cellsHost diseaseAllogeneic bone marrow transplantationT cell-mediated cytotoxicityTumor necrosis factor alphaMajor histocompatibility complex class IGreater serum levelsDonor T cellsBone marrow transplantationCell-mediated cytotoxicityHistocompatibility complex class IWild-type T cellsNecrosis factor alphaComplex class ILethal GVHDAcute graftAlloreactive CD8Histopathologic damageMarrow transplantationSerum levelsAlloantigen stimulationIrradiated murine modelFactor alphaCD8Murine model
2003
Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect
Clouthier S, Cooke K, Teshima T, Lowler K, Liu C, Connolly K, Ferrara J. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect. Transplantation And Cellular Therapy 2003, 9: 592-603. PMID: 14506661, DOI: 10.1016/s1083-8791(03)00230-1.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBone Marrow TransplantationCD4 Lymphocyte CountCD8-Positive T-LymphocytesCell DivisionCell Line, TumorDisease Models, AnimalFemaleFibroblast Growth Factor 10Fibroblast Growth FactorsGraft vs Host DiseaseGraft vs Leukemia EffectHumansInterferon-gammaInterleukin-2IntestinesLipopolysaccharidesLiverLymphocyte CountMiceMice, Inbred C57BLMice, Inbred StrainsRecombinant ProteinsSpleenT-LymphocytesT-Lymphocytes, CytotoxicTransplantation, HomologousTumor Necrosis Factor-alphaConceptsBone marrow transplantationAllogeneic bone marrow transplantationAllogeneic BMT recipientsSystemic GVHDGVL effectHost diseaseBMT recipientsTumor necrosis factor alphaBeneficial GVL effectInduction of GVHDSeverity of graftToxicity of GVHDMurine BMT modelBone marrow inoculumNecrosis factor alphaT cell proliferationRecombinant human keratinocyte growth factorHuman keratinocyte growth factorKeratinocyte growth factorLeukemia effectLeukemia responseSerum levelsMarrow transplantationControl miceOrgan histopathology